Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

epratuzumab-cys-tesirine

An antibody-drug conjugate (ADC) composed of a cysteine-engineered version of epratuzumab (hLL2), a humanized anti-CD22 monoclonal antibody derived from the murine immunoglobulin (Ig) G2a monoclonal antibody LL2 (EPB-2), site-specifically conjugated to the cross-linking cytotoxic agent tesirine (SG3249), a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine dimer (PBD), with potential antineoplastic activity. Upon administration of epratuzumab-cys-tesirine, the epratuzumab moiety targets and binds to the B-cell-specific CD22 receptor and is rapidly internalized. Upon cleavage, the imine groups of tesirine target and bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD22-overexpressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC ADCT-602
anti-CD22/PBD ADC ADCT-602
antibody-drug conjugate ADCT-602
epratuzumab-cys-SG3249
hLL2-cys-PBD
hLL2-cys-SG3249
Code name:ADCT 602
ADCT-602
ADCT602
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search